Constructing Molecular Bridge for High-Efficiency and Stable Perovskite Solar Cells based on P3HT

A molecular bridge of MDN has been demostrated, whose malononitrile group can anchor the perovskite surface while triphenylamine group can form pi-pi stacking with P3HT, to form a charge transport channel and effectively passivate the defects and reduce the recombination for perovskite solar cells.
Constructing Molecular Bridge for High-Efficiency and Stable Perovskite Solar Cells based on P3HT

Organic−inorganic hybrid perovskite solar cells (PSCs) with power conversion efficiency (PCE) over 25% is widely considered one of the most promising photovoltaic technologies for its low-cost manufacturing process and appealing photovoltaic performances. In a typical n−i−p type PSC, hole transport material (HTM) is necessary to extract and transport hole to enhance efficiency, and simultaneously block the moisture ingestion to be the last barrier of perovskite degradation. The doped 2,2’,7,7’-tetrakis[N,N-di(4methoxylphenyl)amino]-9,9’-spirobifluorene (Spiro-OMeTAD) with appropriate hole mobility and energetic level alignment is the most commonly used HTM. However, the achievement of high efficiency has been always accompanied by substantial instability arising from the hygroscopicity and fluidity of dopants that can lead to perovskite corrosion and dopant migration, which is detrimental to the long-term stability and commercialization of PSCs.

Thus, utilizing the existing p-type semiconductors with high hole mobility and mature fabrication process, for example, poly (3-hexylthiophene) (P3HT), as HTMs is another significant attempt. Nevertheless, P3HT adopts the "edge-on" stacking arrangement, that is the alkyl side chains directly contact perovskite film, which normally presents an electronically poor contact at perovskite/P3HT interface, which aggravates the non-radiative recombination loss of PSCs. Thus, the pristine P3HT as a HTM can only achieve a PCE as low as 16% in the state-of-the-art PSCs.

Herein, we have introduced a molecular bridge 2-((7-(4-(bis(4-methoxyphenyl)amino)phenyl)-10-(2-(2-ethoxyethoxy)ethyl)-10H-phenoxazin-3-yl)methylene)malononitrile (MDN) to electronically link perovskite films with P3HT. In such bridge, the malononitrile group shows a strong interaction with the Iodine especially iodine vacancies of the perovskite surface to anchor the perovskite and passivates its surface defects,, while the triphenylamine (TPA) group can form stacking with the segments of P3HT. Finally, a PCE of PSCs of 22.87% has been achieved with an enhanced open-circuit voltage (VOC), from 0.88 ± 0.03 to 1.15 ± 0.02, and fill factor (FF), from 52.91% ± 5.14% to 75.02% ± 3.09%. Furthermore, MDN gives the un-encapsulated device enhanced long-term stability that 92% of its initial efficiency maintain even after two months of aging at 75% relative humidity (RH) follow by one month of aging at 85% RH in the atmosphere, and the PCE does not change after operating at the maximum power point (MPP) under 1 sun illumination (~45 oC in N2) over 500 hours. These distinguished results clearly show a bright future for the industrialization of low-cost, stable, and efficient PSCs by utilizing commercial P3HT-based HTMs.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Subscribe to the Topic

Materials Science
Physical Sciences > Materials Science

Related Collections

With collections, you can get published faster and increase your visibility.

Biomedical applications for nanotechnologies

Overall, there are still several challenges on the path to the clinical translation of nanomedicines, and we aim to bridge this gap by inviting submissions of articles that demonstrate the translational potential of nanomedicines with promising pre-clinical data.

Publishing Model: Open Access

Deadline: Dec 31, 2023

Pre-clinical drug discovery

We welcome studies reporting advances in the discovery, characterization and application of compounds active on biologically or industrially relevant targets. Examples include emerging screening technologies, the development of small bioactive compounds/peptides/proteins, and the elucidation of compound structure-activity relationships, target interactions and mechanism-of-action.

Publishing Model: Open Access

Deadline: Mar 31, 2024